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420 The Journal of Thoracic and Cardbjective: Pulmonary hypertension remains a major problem during the perioper-
tive period for surgical correction of long-standing valvular heart disease. Silde-
afil citrate (INN sildenafil) is a selective phosphodiesterase type 5 inhibitor that is
eing increasingly recognized as a treatment modality for pulmonary hypertension.
here is lack of evidence, however, regarding its pulmonary vasodilatory effect in
nesthetized cardiac surgical patients. We therefore evaluated the effects of silde-
afil on hemodynamics in patients with concomitant pulmonary hypertension un-
ergoing valvular heart surgery in a controlled, prospective, randomized, double-
lind trial.
ethods: Fifty-three patients scheduled for valvular heart surgery with mean
ulmonary arterial pressure greater than 30 mm Hg were randomly treated with
ither 50 mg oral sildenafil (n  26) or placebo (n  27) 10 minutes before
nduction of anesthesia. Hemodynamic variables were measured 5 minutes after
nduction of anesthesia (baseline) and at 30 and 60 minutes after medication.
esults: Patient characteristics and baseline hemodynamics were similar between
roups. Systolic and mean pulmonary arterial pressures and pulmonary vascular
esistance were significantly lower in the sildenafil group at 30 minutes after
edication, without any changes in mean systemic arterial pressure and systemic
ascular resistance.
onclusion: Sildenafil produced significant pulmonary vasodilatory effect relative to
lacebo in anesthetized cardiac surgical patients with pulmonary hypertension. With
espect to the predominant selectivity of sildenafil to pulmonary vasculature shown
n this study and other potentially beneficial effects such as myocardial protection,
se of sildenafil in the intraoperative period in cardiac surgical patients with
ulmonary hypertension should be considered.
ulmonary arterial hypertension (PAH) is characterized by progressive in-
crease in pulmonary vascular resistance leading to right ventricular (RV)
failure and death.1 Pathologic processes behind the complex vascular chan
ssociated with PAH include vasoconstrictor-vasodilator imbalance, thrombosis,
isguided angiogenesis, and inflammation.2,3 Among the vasodilators, nitric oxi
lays a critical role in pulmonary vasomotor regulation, which is mainly mediated
y the guanylate cyclase– cyclic guanylate monophosphate (cGMP) pathway.4
Phosphodiesterase type 5 (PDE5) is an enzyme with predominant presence in the
ascular smooth muscles, where it catabolizes cGMP. PDE5 inhibitors prevent
GMP degradation and thus potentiate the vasodilatory effect of the nitric oxide–
GMP pathway.5-7 Since the introduction of the selective PDE5 inhibitor silde
itrate (INN sildenafil), there has been growing evidence of its efficacy in treatment
f both primary and secondary PAH.8-14 Its availability in oral, inhaled, and intravenous
iovascular Surgery ● December 2006
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A
CDorms, its relative high degree of pulmonary selectivity, and
ts longer half-life than other pulmonary vasodilators are
istinguishing features that make sildenafil a potentially
seful drug for managing perioperative PAH.15,16
PAH with subsequent RV failure remains a major prob-
em during the perioperative period for surgical correction
f congenital and long-standing valvular heart disease.
here is still a lack of evidence, however, regarding the
ntraoperative pulmonary vasodilatory effects of sildenafil
n anesthetized cardiac surgical patients. We therefore eval-
ated the effect of oral sildenafil on hemodynamics in
atients with concomitant PAH undergoing valvular heart
urgery in a controlled, prospective, randomized, double-
lind trial.
aterials and Methods
fter institutional review board approval and surrogate informed
onsent were obtained, 60 patients scheduled for valvular heart
urgery with systolic RV pressure greater than 50 mm Hg, as
easured by preoperative transthoracic echocardiography, were
nrolled. Patients were randomly allocated to either sildenafil or
lacebo (control) group with a computerized randomization table.
atients with preexisting lung parenchymal disease, coronary ar-
ery occlusive disease, hepatic or renal disease, tricuspid regurgi-
ation of at least 2, or New York Heart Association functional class
f at least 3 were excluded. Patients taking nitrates were also
xcluded.
All cardiovascular medications except digoxin and diuretics
ere continued until the day of surgery. On the patient’s arrival at
he operating room, standard monitoring devices were applied,
ncluding a pulmonary arterial catheter (Swan-Ganz CCOmbo
CO/SvO2; Edwards Lifesciences, Irvine, Calif), which was in-
erted through the right internal jugular vein before induction of
nesthesia. After pulmonary arterial catheter insertion, patients
ith mean pulmonary arterial pressures (MPAPs) greater than 30
m Hg were eventually included in this study. Among the 60
atients, 53 patients met this criterion (control group n  27,
ildenafil group n 26) and were treated with either oral sildenafil
50 mg) or placebo with 30 mL of sterile water before induction of
nesthesia. An anesthesiology nurse who was not involved in this
Abbreviations and Acronyms
cGMP  cyclic guanylate monophosphate
CPB  cardiopulmonary bypass
PAH  pulmonary arterial hypertension
PDE5  phosphodiesterase type 5
PVRI  pulmonary vascular resistance index
MPAP mean pulmonary arterial pressure
RV  right ventricle
RVEDVI RV end-diastolic volume index
RVESVI  RV end-systolic volume index
SPAP  systolic pulmonary arterial pressure
SVRI  systemic vascular resistance indextudy prepared the drugs. Investigators and participants were c
The Journal of Thoraciclinded to the assigned groups until their revelation after the study.
en minutes after medication, anesthesia was induced with intra-
enous midazolam (2.0-3.0 mg) and sufentanil (1.5-3.0 g/kg) and
aintained with isoflurane (0.6-1%) and continuous infusion of
ufentanil (0.5-1.5 g/[kg · min]). Neuromuscular blockade was
chieved by administering rocuronium bromide (0.9 mg/kg) and
aintained with continuous infusion of vecuronium bromide (1-2
g/[kg · min]). After the induction of anesthesia, the lungs were
entilated with a tidal volume of 10 mL/kg at a rate of 10
reaths/min in 60% oxygen with air, and positive end-expiratory
ressure was not applied. After that, the accordance of PaCO2 with
nd-tidal carbon dioxide was confirmed before starting the study,
nd respiratory rate was adjusted to maintain PaCO2 between 33
nd 38 mm Hg and pH around 7.4 throughout the study period.
entral temperature, as measured by pulmonary arterial catheter,
as maintained higher than 36°C with warm mattress, forced
arm air blanket, and fluid warmer as necessary.
This study was planned to terminate if systolic arterial pressure
as decreased more than 20% of postinduction value after medi-
ation, necessitating vasoactive drug administration. Hemody-
amic variables were measured before induction of anesthesia
T0), 5 minutes after induction of anesthesia (baseline), and 30 and
0 minutes after medication (T30 and T60, respectively). Baseline
emodynamic values were measured at 18.0  0.8 and 17.8  0.8
inutes after medication in the control and sildenafil groups,
espectively. Hemodynamic measurements included mean arterial
ressure, systolic pulmonary arterial pressure (SPAP), MPAP,
entral venous pressure, cardiac index, RV ejection fraction, RV
nd-diastolic volume index (RVEDVI), and RV end-systolic vol-
me index (RVESVI). Corresponding systemic vascular resistance
ndex (SVRI) and pulmonary vascular resistance index (PVRI)
ere calculated. Surgical incision was withheld until the last
emodynamic measurement was obtained. During the period of
eaning from cardiopulmonary bypass (CPB), numbers of patients
equiring norepinephrine 0.03-0.3 g/[kg · min]) or milrinone (0.3-
.7 g/[kg · min]) were recorded. Patients requiring at least 0.3
g/[kg · min] norepinephrine were considered to require an exces-
ive amount of vasopressors.
Statistical analyses were performed with SPSS 12.0 (SPSS Inc,
hicago, Ill). All data are expressed as mean  SD or number of
atients. Because there was no controlled study comparing the
ffect of oral single dose of sildenafil in cardiac surgical patients,
ample-size calculation was based on a study by Trachte and
olleagues17 with the following assumptions: clinical significan
at .05 with a independent t-test and power to expect a significant
esult at .9, the mean difference between groups at 10 mm Hg with
D at 9 mm Hg of the mean value of MPAP. This generated an
stimate of 18 patients per group. Data were compared between the
roups with 2 test, Fisher exact test, or independent t-test as
ppropriate. Changes between time points within the groups were
ompared with repeated measurements of analysis of variance with
ost hoc comparison by Dunnett test.
esults
ll 53 patients could be successfully studied without any
equirement for vasopressor or inotropic agents during the
eriod of hemodynamic measurements. Also, all patients
ould be successfully weaned from CPB without adverse
and Cardiovascular Surgery ● Volume 132, Number 6 1421
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A
CDvents or requirement of excessive amounts of vaso-
ressors.
Patient characteristics and hemodynamic variables mea-
ured at T0 were similar between the groups (Tables 
nd 3). There were no significant differences in bas
emodynamic variables between the groups. SPAP, MPAP,
VRI, mean arterial pressure, and SVRI after anesthesia
ABLE 1. Patient characteristics
haracteristic
Control
(n  27)
Sildenafil
(n  26) P value
ge (y, mean  SD) 53  12 57 13 .3
ex (male/female) 11:16 10:16 .87
ody surface area (m2) 1.6  0.2 1.6 0.2 .42
isease (No.)
MS 11 12
MR 10 11
MSR 4 2
ASR 9 7
rocedure (No.)
MVR 19 19
AVR 3 1
DVR 5 6
lectrocardiography (NSR/A-fib) 16:11 13:12 .6
S, Mitral stenosis; MR, mitral regurgitation; MSR, mitral stenosis and
egurgitation; ASR, aortic stenosis and regurgitation; MVR, mitral valve
eplacement; AVR, aortic valve replacement; DVR, double valve replace-
ent; NSR, normal sinus rhythm; A-fib, atrial fibrillation.
ABLE 2. Changes in pulmonary and systemic arterial pre
roup T0 Baseline
PAP (mm Hg)
Control 65  21 47  13*
Sildenafil 58  11 45  11*
PAP (mm Hg)
Control 45  13 33  9*
Sildenafil 40  8 32 6*
VRI
dynes · sec · cm5 · m2)
Control 396  193 263  130
Sildenafil 355  138 234  123
AP (mm Hg)
Control 96  15 78  12*
Sildenafil 94  16 78  12*
VRI
dynes · sec · cm5 · m2)
Control 2291 624 1872  565
Sildenafil 2271 839 1809  493
alues are mean  SD. T0, Before induction of anesthesia; Baseline, 5 m
r placebo; T60, 60 minutes after 50 mg oral sildenafil or placebo; SPAP, s
VRI, pulmonary vascular resistance index; MAP, mean systemic arterial
05 versus baseline. ‡P  .05 versus control group.
422 The Journal of Thoracic and Cardiovascular Surgery ● Dec,
baseline values) were significantly decreased in both groups
elative to values at T0 (preinduction values; Table 2). 
eart rate in the sildenafil group and pulmonary capillary
edge pressure in the control group after anesthesia were
ignificantly decreased relative to values at T0 (Table 
At T30, SPAP, MPAP, and PVRI were significantly
ower in the sildenafil group than in the control group
Table 2). And also, SPAP and MPAP at T30 were s
cantly decreased relative to baseline values only in the
ildenafil group (Table 2).
At T60, hemodynamic variables were similar between
he groups. SPAP, MPAP, and PVRI were lower in the
ildenafil group, but without statistical significance (P 
07, P  .087, P  .09, respectively; Table 2). PVR
VEDVI, RVESVI, and SVRI at T60, however, were sig-
ificantly increased relative to baseline values only in the
ontrol group (Tables 2 and 3). Cardiac index was si
antly decreased in both groups, and central venous pressure
n the sildenafil group was significantly increased relative to
aseline (Table 3).
During the period of weaning from CPB, the numbers of
atients requiring norepinephrine (n  9 in both groups)
nd milrinone (n  9 in control group, n  4 in sildenafil
roup) were similar between the groups.
iscussion
n this controlled, prospective, randomized, double-blind
tudy, a single dose of oral sildenafil immediately before
es and vascular resistances
P value
T30 T60 Baseline Control
48  13 52  18
40  8†‡ 45  11 .02 .02
33  8 37 12
29  6†‡ 32  7 .03 .04
290  139 345  163† .02
217  114‡ 273  142 .04
75  11 77  13
74  12 74  12
1821  482 2106  706† .021
1831  613 2001  783
after induction of anesthesia; T30, 30 minutes after 50 mg oral sildenafil
c pulmonary arterial pressure; MPAP, mean pulmonary arterial pressure;
ure; SVRI, systemic vascular resistance index. *P  .05 versus T0. †P ssur
*
*
*
*
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A
CDnduction of anesthesia produced significant pulmonary va-
odilation without eliciting systemic effects 30 minutes after
edication. At 60 minutes after medication, sildenafil pre-
ented the increase in PVRI that occurred in the control
roup, although significant differences in MPAP and PVRI
etween the groups could not be observed.
PAH frequently complicates perioperative management
f cardiac surgical patients with valvular heart disease and
as adverse effects on prognosis. The most important clin-
cal significance of PAH lies in the subsequent RV failure.
ecause CPB exacerbates PAH and the RV is particularly
usceptible to ischemic injury during CPB,18 perioperative
anagement strategies to deal with PAH and RV dysfunc-
ion are necessary. In the area of managing PAH, preserving
oronary perfusion of the RV while decreasing pulmonary
rterial pressure is the desirable goal19; research in recen
ears has therefore been directed toward selective pulmo-
ary vasodilators.
The final messenger for vascular smooth muscle relax-
tion, c-GMP, is metabolized by PDE5.6 Among the variou
hosphodiesterases, PDE5 is the predominant type in the
ormal pulmonary vasculature that may be upregulated after
PB.20 The inhibition of PDE5 is therefore a logical ste
ncrease the bioavailability of cGMP and support endoge-
ous vasodilation in patients with PAH. Sildenafil is a
ABLE 3. Changes in hemodynamic variables
roup T0 Baseline
R (beats/min)
Control 85 14 75  20
Sildenafil 87 21 77  21*
VP (mm Hg)
Control 8 3 10  3
Sildenafil 8 4 9  3
CWP (mm Hg)
Control 30 10 24  8*
Sildenafil 26 7 23  6
I (L /[min · m2])
Control 3.2 0.9 3.2  1.2
Sildenafil 3.3 0.9 3.2  0.8
VEF (%)
Control 23 9 25  10
Sildenafil 27 9 26  10
VESVI (mL/m2)
Control 129 40 134  65
Sildenafil 122 45 143  77
VEDVI (mL/m2)
Control 179 47 167  50
Sildenafil 170 48 189  72
alues are mean  SD. T0, before induction of anesthesia; T0, Before ind
inutes after 50 mg oral sildenafil or placebo; T60, 60 minutes after 50 mg
ulmonary capillary wedge pressure; CI, cardiac index; RVEF, right vent
VEDVI, right ventricular end diastolic volume index. *P  .05 versus T0.otent and selective inhibitor of cGMP-specific PDE5.4 Its m
The Journal of Thoracicotent and relatively selective pulmonary vasodilatory ef-
ects have been demonstrated in animal models,16 in chil-
ren,8 and in adults with PAH.9-13,21-23 In addition, it
eneficial effects with regard to myocardial preconditioning
nd remodeling further advocate its potential use in cardiac
urgical patients.24-26 There has been little experience w
he use of oral sildenafil in adult cardiac surgical patients
ith PAH, mostly limited to the postoperative period. To
he best of our knowledge, this study is the first controlled,
rospective, randomized, double-blind study to confirm sil-
enafil’s pulmonary vasodilatory effect in the intraoperative
eriod.
Pulmonary hemodynamics are markedly variable and
ffected by numerous factors during the perioperative pe-
iod, especially during the period of weaning from CPB and
mmediately thereafter.19 To minimize factors affectin
VRI, hemodynamic values including the baseline values
ere measured under same conditions: (1) general anesthe-
ia with same agents, (2) strict control of mechanical ven-
ilation to maintain normocarbia and normal pH value, (3)
nd withholding of surgical stimulation until after the last
easurement at 60 minutes after medication. In addition, to
nsure constant drug delivery to the stomach without adding
oo much water, the drugs were given before induction of
nesthesia. Thus baseline values were obtained about 18
T30 T60 P vs baseline
73 16 70  13
74 17 73  14
10 3 11 3
9  3 11 4† .002
23 7 26 9
22 5 23 5
3.0 0.8 2.7  0.7† .01
3.0 0.7 2.7  0.7† .003
24 10 24  9
26 9 27 9
146 73 141  52† .031
134 69 125  46
179 58 193  61† .048
193 80 186  65
of anesthesia; Baseline, 5 minutes after induction of anesthesia; T30, 30
ildenafil or placebo; HR, heart rate; CVP, central venous pressure; PCWP,
r ejection fraction; RVESVI, right ventricular end systolic volume index;
.05 versus baseline.uction
oral s
riculainutes after medication in both groups. Although pulmo-
and Cardiovascular Surgery ● Volume 132, Number 6 1423
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A
CDary vasodilatory effects of oral sildenafil have been re-
orted after 12 to 15 minutes, mean time to peak concen-
ration is 0.8 to 0.9 h with most of the studies reporting time
o maximal pulmonary vasodilatory effect of 30 to 60 min-
tes.12,15,27 In accordance with this value, the baseline -
odynamic values were similar between the groups in this
tudy.
As with previous reports, we could observe significant
ecreases in pulmonary arterial pressure and PVRI without
ny changes in mean arterial pressure and SVRI, which
upports sildenafil’s predominantly selective activity on
ulmonary vasculature.9 Sildenafil also had clinically insi-
ificant effects on cardiac index, heart rate, and other he-
odynamic variables measured in this study. We could not
bserve any statistically significant subsequent improve-
ent in RV ejection fraction or reduction in RVEDVI and
VESVI in the sildenafil group, even at T30 when maximal
ulmonary vasodilation had occurred. The findings that
VESVI and RVEDVI were significantly increased in the
ontrol group at T60 relative to baseline values and that
VESVI showed a trend toward decrease in the sildenafil
roup, however, indicate that there may have been potential
mprovement in RV performance.
Sildenafil has an elimination half-life of 3.7 hours,24 and
pulmonary vasodilatory effect lasting for at least 3 hours
ithout affecting systemic arterial pressure has been
eported.5 In this study, significant intergroup differences
ulmonary arterial pressure could not be observed after 60
inutes of medication. The finding that PVRI and RVEDVI
nd RVESVI were significantly increased relative to base-
ine values only in the control group, however, indicates that
here may have been some beneficial effect of sildenafil at
his time point. Possible explanations are that adverse ef-
ects of continued mechanical ventilation on PVRI attenu-
ted the vasodilatory effect of sildenafil. Reduced absorp-
ion of sildenafil as a result of general anesthesia also may
ave affected the results. Even though 50 mg oral sildenafil
as been proved to be sufficient to produce significant
ulmonary vasodilation,12,28 studies with oral sildenafil 
nesthetized animals have reported reduced plasma concen-
ration rather than delayed absorption,29,30 which could no
e verified in this study and is a limitation of this study.
urther investigations regarding pharmacokinetics of oral
ildenafil in anesthetized patients are therefore necessary to
larify optimal dosing and dosing interval.
In conclusion, oral sildenafil produced significant pulmo-
ary vasodilatory effects relative to placebo in anesthetized
ardiac surgical patients with PAH. Because of the predom-
nant selective activity of sildenafil on the pulmonary vas-
ulature shown in this study and such other potentially
eneficial effects as myocardial protection, use of sildenafil
n the intraoperative period in cardiac surgical patients with
AH should be considered.
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